Give the Receptor a Brake: Slowing Gastric Emptying by GLP-1
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The conventional view of endocrinologists is that glucose regulation after a meal depends on the interplay of insulin and glucagon secretion, hepatic glucose production, and glucose disposal. However, in recent years the role of gastric motility and its effect on glucose appearance from the gut have been revived as a determinant of glucose tolerance (1,2). This is due in great part to the availability of diabetes therapeutics that act, in part, by delaying gastric emptying (GE). Yet it is important to note that much of the variance in oral glucose tolerance is accounted for by differences in GE rate, an observation made over two decades ago (1). Even a minor perturbation in GE carries a substantial impact on postprandial glycemia in healthy individuals (1) and those with diabetes (3), such that more rapid GE results in a greater initial glycemic response and slower gastric delivery of meal contents to the intestine leads to smaller glucose excursion (4). Glucagon-like peptide 1 (GLP-1) normalizes glycemia by promoting glucose-dependent insulin secretion and inhibiting glucagon secretion in the fasting state (5). A deceleration of GE is also characteristic of GLP-1 action and occurs both in patients with type 2 diabetes (T2D) and healthy individuals (6–8). In fact, glucose lowering by GLP-1 was significantly attenuated when the actions on GE were overridden by treatment with erythromycin (9). This has led to questions as to whether islet or gastrointestinal effects of GLP-1 predominate in its effects on glycemia (10). Long-acting GLP-1 receptor (GLP-1R) agonists, recently developed and now commonly used in the treatment of T2D, stimulate insulin secretion and reduce GE (5), but the relative impact of these two physiologic actions on acute and chronic control of blood glucose is not clear. Recent studies have raised the …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 2×
“Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.”
BackgroundDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects
Horowitz, M., Edelbroek, M. A. L., Wishart, J. M., & Straathof, J. W. (1993) · Diabetologia · doi:10.1007/bf00400362 · Cited by 469 · cited 3×
“Even a minor perturbation in GE carries a substantial impact on postprandial glycemia in healthy individuals (1) and those with diabetes (3), such that more rapid GE results in a greater initial glycemic response and slower gastric delivery of meal contents to the intestine leads to smaller glucose excursion (4).”
BackgroundNauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · cited 4×
“Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.”
BackgroundResultInfluentialUmapathysivam, M. M., Lee, M. Y., Jones, K. L., Annink, C. E., Cousins, C. E., Trahair, L. G., Rayner, C. K., Chapman, M. J., Nauck, M. A., Horowitz, M., et al. (2014) · Diabetes · doi:10.2337/db13-0893 · Cited by 193 · cited 3×
“Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.”
BackgroundMeier, J. J., Kemmeries, G., Holst, J. J., & Nauck, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2212 · Cited by 146
Quddusi, S., Vahl, T. P., Hanson, K., Prigeon, R. L., & D’Alessio, D. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.791 · Cited by 111 · cited 2×
“Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.”
BackgroundSelf-citationPancreatic polypeptide: a unique model for vagal control of endocrine systems
Schwartz, T. W. (1983) · Journal of the Autonomic Nervous System · doi:10.1016/0165-1838(83)90134-0 · Cited by 71
Lieb, J., & Balter, A. (1984) · Medical Hypotheses · doi:10.1016/0306-9877(84)90018-5 · Cited by 30 · cited 2×
“Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.”
Background
Research works printed but not linked: 14
- Vella, 2004, The gastrointestinal tract and glucose tolerance, Curr Opin Clin Nutr Metab Care, 7, 479, 10.1097/01.mco.0000134375.01310.97 · DOI
- Jones, 1995, Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus, J Nucl Med, 36, 2220
- Gonlachanvit, 2003, Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients, Dig Dis Sci, 48, 488, 10.1023/A:1022528414264 · DOI
- Nauck, 1997, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, Am J Physiol, 273, E981
- Meier, 2003, Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes, J Clin Endocrinol Metab, 88, 2719, 10.1210/jc.2003-030049 · DOI · Paper page
- Nauck, 1999, Is glucagon-like peptide 1 an incretin hormone?, Diabetologia, 42, 373, 10.1007/s001250051165 · DOI
- Rao, 2011, Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies, Neurogastroenterol Motil, 23, 8, 10.1111/j.1365-2982.2010.01612.x · DOI · Paper page
- Nauck, 1993, Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations, J Clin Endocrinol Metab, 76, 912
- Holmes, 2009, Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions, J Physiol, 587, 4749, 10.1113/jphysiol.2009.175067 · DOI · Paper page
- Wettergren, 1998, Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow, Am J Physiol, 275, G984
- Plamboeck, 2013, The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty, Am J Physiol Gastrointest Liver Physiol, 304, G1117, 10.1152/ajpgi.00035.2013 · DOI · Paper page
- Broide, 2013, GLP-1 receptor is expressed in human stomach mucosa: analysis of its cellular association and distribution within gastric glands, J Histochem Cytochem, 61, 649, 10.1369/0022155413497586 · DOI
- Klemenska, 2009, Bioactivation of organic nitrates and the mechanism of nitrate tolerance, Cardiol J, 16, 11
- Henry, 2013, Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes, Diabetes Care, 36, 2559, 10.2337/dc12-2410 · DOI · Paper page
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“121,134 GIP, another insulin secretion agonist, helps release insulin, particularly after eating, enhancing the effects of GLP-1 and thereby improving the overall therapeutic ef fi cacy of the drug.”
BackgroundThe SEARCH for Diabetes in Youth Study: Rationale, Findings, and Future Directions
Hamman, R. F., Bell, R. A., Dabelea, D., D’Agostino, R. B., Dolan, L., Imperatore, G., Lawrence, J. M., Linder, B., Marcovina, S. M., Mayer-Davis, E. J., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0574 · Cited by 619
Bile acid metabolism and signaling, the microbiota, and metabolic disease
Cai, J., Rimal, B., Jiang, C., Chiang, J. Y. L., & Patterson, A. D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108238 · Cited by 497
Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14280 · Cited by 427
Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities
Nadeau, K. J., Anderson, B. J., Berg, E. G., Chiang, J. L., Chou, H., Copeland, K. C., Hannon, T. S., Huang, T. T.-K., Lynch, J. L., Powell, J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1066 · Cited by 381
Metadata
- Authors
- Tong, J., & D’Alessio, D.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-01-16
- Volume
- 63
- Issue
- 2
- Pages
- 407-409
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2081436875
- Cited by
- 63
- References
- 11
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.